ArticleChinese journal of integrative medicine2026
Polysaccharide of Danggui Buxue Decoction Attenuates Colorectal Cancer via Modulating Intestinal Microflora and Metabolites.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progress on the regulation of colorectal cancer and cardio-oncology by the gut microbiota and nutrients.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore whether polysaccharide of Danggui Buxue Decoction (formula polysaccharide, FP) could attenuate colorectal cancer (CRC) via modulating intestinal microflora and metabolites.
methodsA total of 30 male C57BL/6 mice were randomly assigned to 3 groups according to body weight, including normal control, CRC model and FP groups (n=10). Dextran sulfate sodium and azoxymethane were used to induce CRC model. The mice in FP group were treated with FP [0.9 g/(kg·d)] for 8 weeks. Then the coloretal length, weight and tumors number of colorectal tissues were observed. Colonic tissues were stained with hematoxylin and eosin to evaluate the histological changes. Tight junction proteins including claudin 1 and zonula occludens-1 (ZO-1) were detected using immunohistochemistry. Serum concentrations of endothelial cell specific molecule-1 and carcino embryonic antigen were determined using enzyme-linked immunosorbent assays. Toll-like receptor 4 (TLR4)/nuclear transcription factor-κB (NF-κB) p65 signal-related mRNA and proteins expressions were detected using real-time polymerase chain reaction and Western blot, respectively. Feces samples were detected with 16S rRNA and liquid chromatography-mass spectrometry and non-targeted metabolomics sequencing was used to analyze the composition of intestinal microbiota and metabolic changes.
resultsFP significantly inhibited colorectal tumor growth, attenuated body weight loss, repaired colonic structure, improved intestinal barrier dysfunction, reduced colonic inflammatory cytokine levels and inhibited TLR4/NF-κB pathway related mRNA and protein expressions (all P<0.01). Moreover, FP altered the gut microbiota composition of CRC mice dramatically, characterized by a reduction of Firmicutes-Bacteroidetes ratio at the phylum level. FP suppressed Lachnospiraceae_NK4A136_group, Odoribacter and Romboutsia (P<0.05 or P<0.01), and elevated the abundance of Dubosiella, Candidatus_Saccharimonas and Alloprevotella at the genus level (P<0.01). Non-targeted metabolomics sequencing detected significant differences in metabolites, and the functions of differential metabolites were focused on regulating amino acid metabolism, lipid metabolism and metabolism of cofactors and vitamins.
conclusionsFP attenuates colonic injury and intestinal inflammatory response in CRC mice, repairs disrupted-intestinal microbiota, and improves metabolites. This research provides experimental basis for application of FP as a potential therapeutic agent for CRC.
Indexed as
Identifiers
41249758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.